Clene (CLNN)
NASDAQ:CLNN
Top Page
Clene
(NASDAQ:CLNN)
Select Model
Select Model
Rating:50Neutral
Price Target:
$5.00
▼(-18.17% Downside)
Action:ReiteratedDate:03/17/26
The score is held down primarily by very weak financial performance (large losses, sustained cash burn, and negative equity). Offsetting factors include improving technical momentum and supportive corporate developments (financing/runway extension and regulatory steps), while valuation remains unfavorable due to losses and no dividend.
Positive Factors
Non-dilutive NIH funding
A reimbursable NIH subaward of up to $8M funds the Expanded Access Program and covers near-term clinical work without immediate equity issuance. Preserving IP control and reimbursement terms provides non-dilutive runway support and reduces near-term financing pressure for pivotal regulatory interactions.
Negative Factors
Negative equity
Negative shareholders' equity and a materially shrinking asset base signal solvency stress and weaker financial flexibility. This structural capital shortfall constrains borrowing capacity and increases reliance on external financing, elevating dilution risk and limiting strategic options over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive NIH funding
A reimbursable NIH subaward of up to $8M funds the Expanded Access Program and covers near-term clinical work without immediate equity issuance. Preserving IP control and reimbursement terms provides non-dilutive runway support and reduces near-term financing pressure for pivotal regulatory interactions.
Read all positive factors
Clene (CLNN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$74.67M
Dividend YieldN/A
Average Volume (3M)85.56K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue Growth-49.17%
EPS Growth23.37%
CountryUS
Employees75
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.93
Shares Outstanding11,778,307
10 Day Avg. Volume106,026
30 Day Avg. Volume85,560
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-3.29
Price to Sales (P/S)289.36
P/FCF Ratio-3.11
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue387.92
Enterprise Value/Gross Profit494.17
Enterprise Value/Ebitda-3.59
Forecast
1Y Price Target
$32.25Price Target Upside427.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.89
Revenue Forecast (FY)$240.00K
Clene Business Overview & Revenue Model
Company Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trial...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Clene has not consistently generated product sales from approved therapies; its ability to generate operating revenue is primarily tied to clinical development and financing activities. The company’s ...
Clene Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 200.00K | 342.00K | 654.00K | 473.00K | 723.00K |
| Gross Profit | 157.00K | 272.00K | 533.00K | 447.00K | 434.00K |
| EBITDA | -21.59M | -33.69M | -43.24M | -25.60M | -8.34M |
| Net Income | -26.17M | -39.40M | -49.50M | -29.92M | -9.74M |
Balance Sheet | |||||
| Total Assets | 18.13M | 27.34M | 52.34M | 44.49M | 63.06M |
| Cash, Cash Equivalents and Short-Term Investments | 5.19M | 12.15M | 35.00M | 23.32M | 50.29M |
| Total Debt | 21.67M | 20.84M | 32.16M | 31.82M | 24.04M |
| Total Liabilities | 35.72M | 36.19M | 38.95M | 41.26M | 50.47M |
| Stockholders Equity | -17.59M | -8.86M | 13.39M | 3.24M | 12.60M |
Cash Flow | |||||
| Free Cash Flow | -18.59M | -21.34M | -30.50M | -44.19M | -35.96M |
| Operating Cash Flow | -18.55M | -21.33M | -30.17M | -39.01M | -34.62M |
| Investing Cash Flow | -39.00K | 6.32M | -1.50M | -10.16M | -1.33M |
| Financing Cash Flow | 11.52M | -1.53M | 42.16M | 17.25M | 27.11M |
Clene Technical Analysis
Positive
6.11
Price Trends
5.11
Positive
5.90
Positive
6.02
Positive
Market Momentum
0.20
Negative
58.15
Neutral
78.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLNN, the sentiment is Positive. The current price of 6.11 is above the 20-day moving average (MA) of 5.66, above the 50-day MA of 5.11, and above the 200-day MA of 6.02, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 58.15 is Neutral, neither overbought nor oversold. The STOCH value of 78.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLNN.
Clene Risk Analysis
Clene disclosed 66 risk factors in its most recent earnings report. Clene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clene Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
52 Neutral | $106.75M | -0.98 | -55.04% | ― | ― | 44.59% | |
50 Neutral | $74.67M | -2.21 | 240.83% | ― | -49.17% | 23.37% | |
48 Neutral | $32.46M | -4.89 | -695.82% | ― | -0.66% | -8.43% | |
47 Neutral | $233.12M | -2.32 | -162.49% | ― | ― | 5.51% | |
42 Neutral | $4.33M | -0.56 | -68.21% | ― | ― | ― |
* Consumer Defensive Sector Average
CLNN
Clene
6.11
3.03
98.38%
DYAI
Dyadic International
0.89
-0.32
-26.45%
AKTX
Akari Therapeutics
3.83
-40.69
-91.40%
ESLA
Estrella Immunopharma
1.84
0.97
111.49%
ANTX
AN2 Therapeutics, Inc.
2.97
1.66
126.72%
CAMP
CAMP4 Therapeutics Corporation
4.49
2.71
152.25%
Clene Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Clene Secures Third-Year NIH Subaward for ALS Program
Positive
Mar 17, 2026
On March 13, 2026, Clene entered into a third-year subaward agreement with New York University for up to $8.0 million under a previously announced four-year, $45.1 million National Institutes of Health grant supporting an Expanded Access Program f...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Clene outlines 2026 regulatory milestones and ALS strategy
Positive
Feb 24, 2026
On February 24, 2026, Clene issued a letter to stockholders outlining key regulatory and clinical milestones it expects for CNM-Au8 in 2026, anchored by an operating cash runway projected into the fourth quarter of 2026 after a January capital rai...
Business Operations and StrategyPrivate Placements and Financing
Clene Announces Multi-Tranche Financing to Extend Cash Runway
Positive
Jan 13, 2026
On January 8, 2026, Clene Inc. entered into securities purchase agreements with institutional, existing and insider investors for a registered direct offering structured in three tranches totaling more than $28 million in potential gross proceeds,...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Clene Advances CNM-Au8 ALS Program with FDA Meeting
Positive
Jan 12, 2026
On January 12, 2026, Clene Inc. announced that the U.S. Food and Drug Administration granted the company an in-person Type C meeting in the first quarter of 2026 to discuss biomarker data supporting a potential new drug application for CNM-Au8 in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.